Senseonics
The continuous glucose monitoring system can be used to measure glucose levels in adults with diabetes for up to six months.
The arrangement comes alongside new eight-figure investments into the CGM maker, whose business looked to be in dire straits earlier this year.
The Eversense Bridge program is geared toward patients with high-deductible insurance plans or plans that don't cover the full cost of Eversense CGM, and allows them to purchase the system for $99.
Also: Senseonics and CardinalAnalytx hire new chief medical officers; WithMe Health appoints CEO.
Users of the Eversense CGM will be able to transfer their data to Glooko's online diabetes management platform.
Also: Senseonics' Eversense is cleared for use during an MRI; Warby Parker's AR app update.
Not two months after getting the FDA nod for its implantable CGM, Eversense, Senseonics held its Q2 earnings call reporting a increase in year over year revenues.
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players.
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States.
Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche.